Cancer Care Engineering Colorectal Cancer Gabriela Chiorean, M.D. May 26, 2010

Rationale Perform OMICs of healthy, polyps, cancer Perform OMICs of healthy, polyps, cancer Compare OMICs between cancer, polyps and healthy: develop new screening and risk assessment tools Compare OMICs between cancer, polyps and healthy: develop new screening and risk assessment tools Analyse changes in OMICs with treatment and correlate with response/toxicity: predictive markers Analyse changes in OMICs with treatment and correlate with response/toxicity: predictive markers

Schema IUCRO-0221 CCE in CRC SAMPLESSAMPLES Blood (Serum) 7 mL red top Metab, vit D Blood (Plasma) 21 mL purple top Genomics, lipidomics, glycoproteomics N=270 Stratification: -Healthy (n=90) -Polyps (n=90) -Cancer (n=90) stg 1/2 stg 3 stg 4 metastatic Tissue 10 mg polyp or 50 mg cancer / 50 mg normal tissue SHIPDRYICESHIPDRYICE 8-hr fasting

Samples Collection Healthy Controls Screening Colonoscopy – GI Clinic Label specimens Healthy if no polyps/tumor Blood Questionnaires N= 5 6/09 N=74 5/10

Samples Collection Adenomatous Polyps Screening Colonoscopy – GI Clinic Label specimens Polyp Polyps identified Tissue procurement/Research specialist -Polyp cut in ½ -Place in tube with no preservative -Freeze at -70 o C Blood Questionnaires N= 3 6/09 N= 65 5/10

Samples Collection Cancer Surgery Tissue: tumor, normal mucosa Blood Questionnaires ChemotherapyFollow-up Every 3 months Up to 24 months N=8 6/09 N= 34 5/10

Sample Acquisition 4/2009-5/2010 Healthy n=74 Healthy n=74 blood, questionnaires blood, questionnaires Polyps n=65 Polyps n=65 blood, blood, tissue (n=43) tissue (n=43) questionnaires questionnaires Cancer n=34 Cancer n=34 blood blood tissue (n=4) tissue (n=4) questionnaires questionnaires